This ultimately then led to multiple front-line strategies in stage IV NSCLC including immunotherapy monotherapy in PD-L1 tumor proportion score ≥ 50%, chemotherapy with immunotherapy, dual ICI therapy with PD-1/PD-L1 and CTLA-4 inhibitor therapy [31–36]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.